hepatitis C

FDA Approves Gilead’s Epclusa for Children with Hepatitis C
FDA Approves Gilead’s Epclusa for Children with Hepatitis C
BioSpace
Epclusa
hepatitis C
Gilead Sciences
FDA
pediatric
Flag link:
European regulators expand use of AbbVie's two-month hep C regimen
European regulators expand use of AbbVie's two-month hep C regimen
Endpoints
AbbVie
Europe
hepatitis C
Maviret
Flag link:
Where Will Gilead Sciences Be in 10 Years?
Where Will Gilead Sciences Be in 10 Years?
Motley Fool
Gilead Sciences
HIV
hepatitis C
Flag link:
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
Motley Fool
Enanta Pharmaceuticals
earnings
AbbVie
Mavyret
hepatitis C
Flag link:
Merck loses bid to revive $2.54 billion patent verdict against Gilead
Merck loses bid to revive $2.54 billion patent verdict against Gilead
Yahoo/Reuters
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
BioSpace
hepatitis C
Washington state
AbbVie
Louisiana
Gilead Sciences
Asegua Therapeutics
Flag link:
FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?
FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?
Endpoints
AbbVie
Mavyret
hepatitis C
FDA
Flag link:
FDA issues safety warning for newer hepatitis C drugs following patient deaths
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
FDA
hepatitis C
FAERS
AbbVie
Mavyret
Merck
Zepatier
Gilead Sciences
Vosevi
Flag link:
5 Things You Need to Know From AbbVie's Q2 Earnings Results
5 Things You Need to Know From AbbVie's Q2 Earnings Results
Motley Fool
AbbVie
Humira
Venclexta
Imbruvica
hepatitis C
earnings
Flag link:
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
Drug Channels
JAMA
drug pricing
340B
hepatitis C
Flag link:
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
Biopharma Dive
hepatitis C
Medicaid
Netflix model
Louisiana
Gilead Sciences
CMS
Flag link:
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
BioCentury
Washington
Netflix model
hepatitis C
BGI Genomics
China
distribution
Flag link:
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
Biopharma Dive
AbbVie
hepatitis C
Netflix model
Washington state
Flag link:
Louisiana has picked its 'Netflix' hepatitis C partner: Gilead's new generics unit
Louisiana has picked its 'Netflix' hepatitis C partner: Gilead's new generics unit
Fierce Pharma
Louisiana
Gilead Sciences
hepatitis C
Asegua Therapeutics
Netflix model
Flag link:
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Fierce Pharma
hepatitis C
AbbVie
Gilead Sciences
Louisiana
Netflix model
Flag link:
Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections
Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections
Stat
Purdue Pharma
oxycontin
abuse-resistant painkillers
hepatitis C
Flag link:
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Fierce Pharma
Gilead Sciences
hepatitis C
Epclusa
drug ads
television ads
Flag link:
7 Things to Expect for Gilead Sciences in 2019
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
Flag link:
Did Gilead Sciences Make an $11 Billion Blunder?
Did Gilead Sciences Make an $11 Billion Blunder?
Motley Fool
Gilead Sciences
Pharmasset
hepatitis C
Flag link:
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
Fierce Pharma
AbbVie
hepatitis C
Mavyret
Medicines Patent Pool
Flag link:

Pages